PuraPharm Corporation Limited

1498

KYG7306Y1044

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:03 23/05/2024 pm IST			5-day change	1st Jan Change
0.77 ^HKD	0.00%		0.00%	-14.44%

01/04	PuraPharm's Net Loss Shrinks in 2023; Revenue Falls 9%	MT
28/03	PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ended December 31, 2020

February 21, 2021 at 03:34 pm IST

PuraPharm Corporation Limited provided earnings guidance for the year ended December 31, 2020. The company expected that the Group's will record a net profit of approximately HKD 30 million for financial year 2020, as compared with the net loss of HKD 227.3 million for financial year ended 31 December 2019.

Latest news about PuraPharm Corporation Limited

PuraPharm's Net Loss Shrinks in 2023; Revenue Falls 9%	01/04	MT
PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director	20/11	CI
PuraPharm Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director	14/23/14	CI
PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
PuraPharm Grants Nearly 8 Million Options	30/22/30	MT
Purapharm Swings to H1 Loss on Lower Sales	29/22/29	MT
PuraPharm Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2022	28/22/28	CI
Purapharm Corporation Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2022	12/22/12	CI
Purapharm Corporation Limited Announces Retirement of Non-Executive Director	31/22/31	CI
Purapharm Turns to Loss in 2021 on Impairment Loss of Goodwill; Shares Fall 4%	30/22/30	MT
PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2021	29/22/29	CI
Purapharm Forecasts Turn to Loss in 2021	28/22/28	MT
PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021	25/22/25	CI
Purapharm Corporation Limited Announces Change of Headquarter And principal Place of Business in Hong Kong	16/21/16	CI
Purapharm : Cancels Sale of Intellectual Property Assets to BAGI Research	06/21/06	MT
PuraPharm : Books Higher Profit, Revenue in H1	23/21/23	MT
Purapharm Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2021	20/21/20	CI
PuraPharm Corporation Limited Announces Change of CFO	29/21/29	CI
Purapharm Corporation Limited Announces Executive Changes	29/21/29	CI
Purapharm Corporation Limited Announces Re-Designation of Cheong Shin Keong from an Executive Director to Non-Executive Director	28/21/28	CI
PuraPharm Corporation Limited Announces Retirement of Directors and Change in Composition of the Board Committees	28/21/28	CI
Purapharm : Extends Long Stop Date of Intellectual Property Asset Sale	26/21/26	MT
Purapharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2020	25/21/25	CI

Chart PuraPharm Corporation Limited

Duration

Period

More charts

Company Profile

PuraPharm Corporation Ltd is an investment holding company principally engaged in the concentrated Chinese medicine granule (CCMG) businesses. The Company operates through five business segments. The China CCMG segment is mainly engaged in the production and sales of CCMG products in China. The Hong Kong CCMG segment is mainly engaged in the sales of CCMG products, excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment is mainly engaged in the production and sales of healthcare products in Hong Kong and China. The Clinics segment is mainly engaged in the provision of Chinese medical diagnostic services and sales of CCMG products through self-operated clinics. The Plantation segment is mainly engaged in the plantation and trading of raw Chinese herbs, and the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
PURAPHARM CORPORATION LIMITED	-14.44%	38.97M
DONG-E-E-JIAO CO.,LTD.	+39.27%	6.07B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-18.60%	4.42B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+3.27%	3.26B
TASLY PHARMACEUTICAL GROUP CO., LTD	-15.69%	3B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-5.88%	2.47B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+43.78%	1.89B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-11.89%	1.63B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-4.67%	1.6B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-14.39%	1.54B

Alternative Medicine